In addition, because many cells undergo apoptosis at the site of allergic inflammation [71,72,73], and considering the PS-CD300a-based self-regulation capacity of, at least, mast cells, CD300a may play an important anti-inflammatory role in allergic responses and may be a potential prophylactic and/or therapeutic target for the treatment of allergic diseases. This evidence concerns the gene CD300A and allergic disease.